Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face ...

Regeneron Pharmaceuticals Inc. closed 54.89% short of its 52-week high of $1,211.20, which the company reached on August 27th ...

In January 2025, Melanoma Institute Australia announced a phase II, open label, randomised trial of ipilimumab and nivolumab ...

As Fierce Pharma points out, patent expirations are a routine occurrence in the pharmaceutical world, but 2025 stands out for ...

Guggenheim analyst Yatin Suneja lowered the firm’s price target on Regeneron (REGN) to $940 from $950 and keeps a Buy rating on the shares. The ...

ADAR1 Capital Management LLC dramatically boosted its holdings in Regeneron Pharmaceuticals by 56.3% during Q4, grabbing 1,361 shares worth nearly $969,000. Several other institutional investors also ...

The stock's rise snapped a four-day losing streak.

Trump on Tuesday said his administration will be announcing a “major” tariff on pharmaceuticals “very shortly.” ...

In the European Union and the United Kingdom, aflibercept 8mg (Eylea HD in the US) is currently approved for neovascular ...

Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Regeneron (REGN) to $1,081 from $1,150 and keeps an Overweight rating ...

Fmr LLC gave Regeneron the cold shoulder, trimming its stake by 20.9% and dropping 2.16 million shares in Q4. This move ...

Vertex continues to capitalize on its leadership in cystic fibrosis (CF) treatments, where its blockbuster drug Trikafta is ...